Investigation of annexin A5 as a biomarker for Alzheimer’s disease and Dementia with Lewy bodies

3^rd International Conference on Biomarkers & Clinical Research

July 2-4, 2012 Embassy Suites Las Vegas, USA

Hitoshi Sohma

Keynote: J Mol Biomark Diagn

Abstract :

Alzheimer?s disease (AD) differs from other forms of dementia in its relation to amyloid beta peptide (A☐42). Using a cell culture model we previously identified annexin A5, a Ca2+ and phospholipid binding protein, as an AD biomarker. Plasma level of annexin A5 was significantly higher in AD patients compared to that in a control group. As AD shares clinical and pathological features with Dementia with Lewy bodies (DLB), the present study was done to examine the similarity of AD and DLB using the plasma AD biomarker annexin A5.

Biography :

Hitoshi Sohma completed his Ph.D. in biochemistry at Hokkaido University, Japan, focusing on Ca2+-signaling in cell-cell communications, and his postdoctoral studies at the National Institute of Mental Health, NIH. He is a professor in the Department of Educational Development, Sapporo Medical University Center for Medical Education, Sapporo, Japan. He is also involved in both pathobiochemical research and the management of medical education at the university.